Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GALWAY, IRELAND , AUG. 14, 2025 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OFMEDTRONIC PLC (NYSE:MDT) ONTHURSDAY, AUGUST 14, 2025, APPROVED THE COMPANY'S CASH DIVIDEND FOR THE SECOND QUARTER OF FISCAL YEAR 2026 OF $0.71PER ORDINARY SHARE. THIS QUARTERLY DECLARATION IS CONSISTENT WITH THE DIVIDEND INCREASE ANNOUNCEMENT MADE BY THE COMPANY INMAY 2025.

MEDTRONIC ANNOUNCES CASH DIVIDEND FOR SECOND QUARTER OF FISCAL YEAR 2026

CHICAGO--(BUSINESS WIRE)--FOURKITES, THE GLOBAL LEADER IN AI-DRIVEN SUPPLY CHAIN TRANSFORMATION, TODAY ANNOUNCED THAT DOV SHENKMAN, CEO AND FOUNDING MEMBER OF ATID GROUP LLC, HAS JOINED ITS STRATEGIC ADVISORY COUNCIL. SHENKMAN BRINGS OVER 40 YEARS OF GLOBAL SUPPLY CHAIN AND OPERATIONS LEADERSHIP EXPERIENCE ACROSS HEALTHCARE, RETAIL, AUTOMOTIVE, AND TECHNOLOGY INDUSTRIES TO FOURKITES' ADVISORY COUNCIL, WHERE HE WILL PROVIDE INSIGHT INTO INNOVATION OPPORTUNITIES AND MARKET EXPANSION. AT ATID GRO.

FORMER MEDTRONIC SUPPLY CHAIN LEADER JOINS FOURKITES' STRATEGIC ADVISORY COUNCIL

GALWAY, IRELAND , AUG. 5, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS ON TUESDAY, AUGUST 19, 2025, FOR ITS FIRST QUARTER OF FISCAL YEAR 2026, WHICH ENDED ON FRIDAY, JULY 25, 2025, A NEWS RELEASE CONTAINING SUMMARY FINANCIAL INFORMATION WILL BE ISSUED AT APPROXIMATELY 5:45 A.M. CENTRAL DAYLIGHT TIME (CDT) AND WILL BE AVAILABLE AT HTTPS://NEWS.MEDTRONIC.COM A VIDEO WEBCAST TO DISCUSS RESULTS WILL BEGIN AT 7:00 A.M.

MEDTRONIC TO ANNOUNCE FINANCIAL RESULTS FOR ITS FIRST QUARTER OF FISCAL YEAR 2026

GALWAY, IRELAND , JULY 21, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN MEDICAL TECHNOLOGY, TODAY ANNOUNCED CE (CONFORMIT EUROPENNE) MARK IN EUROPE TO EXPAND INDICATIONS OF THE MINIMED 780G SYSTEM FOR USE BY INDIVIDUALS AGED 2 YEARS AND OLDER, DURING PREGNANCY, AS WELL AS TYPE 2 INSULIN-REQUIRING DIABETES. TO GAIN CE MARK FOR THIS EXPANSION OF INDICATIONS, PUBLISHED CLINICAL DATA IN 26-YEAR-OLDS, PREGNANT WOMEN, AND PEOPLE LIVING WITH TYPE 2 DIABETES WAS REVIEWED.

MEDTRONIC SECURES CE MARK FOR MINIMED 780G SYSTEM FOR INSULIN-REQUIRING PEOPLE WITH DIABETES INCLUDING EXPANDED INDICATIONS IN CHILDREN AS YOUNG AS TWO, DURING PREGNANCY, AND FOR TYPE 2 DIABETES

GALWAY, IRELAND , JULY 8, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED THE APPOINTMENT OF CHAD SPOONER AS CHIEF FINANCIAL OFFICER (CFO) OF MINIMED, IN ADVANCE OF ITS INTENDED SEPARATION INTO A STANDALONE, PUBLIC COMPANY. EFFECTIVE JULY 14, 2025, CHAD WILL BE RESPONSIBLE FOR OVERSEEING THE FINANCE FUNCTION FOR MEDTRONIC DIABETES AND SUPPORTING INITIATIVES AIMED AT ACCELERATING PROFITABLE GROWTH AND DELIVERING SHAREHOLDER VALUE AS IT PREPARES TO BECOME FULLY INDEPENDENT.

MEDTRONIC ANNOUNCES APPOINTMENT OF MINIMED CHIEF FINANCIAL OFFICER AHEAD OF INTENDED SEPARATION INTO STANDALONE COMPANY

GALWAY, IRELAND , JUNE 23, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS APPOINTED DR. JOON LEE, CEO AT EMORY HEALTHCARE, INC., TO THE BOARD AS AN INDEPENDENT DIRECTOR, EFFECTIVE JUNE 18, 2025. DR. LEE WILL SERVE ON THE SCIENCE AND TECHNOLOGY COMMITTEE AND COMPENSATION AND TALENT COMMITTEE OF THE BOARD.

MEDTRONIC BOARD APPOINTS DR. JOON LEE AS A NEW DIRECTOR

GALWAY, IRELAND , JUNE 12, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED MINIMED AS THE NAME FOR THE PLANNED NEW DIABETES COMPANY FOLLOWING THE INTENDED SEPARATION. THE NAME HONORS THE COMPANY'S ROOTS, REFLECTING ITS ORIGINAL NAME PRIOR TO ITS ACQUISITION BY MEDTRONIC IN 2001, AND A DEEP 40-YEAR HISTORY OF BEING AT THE FOREFRONT OF TRANSFORMING DIABETES CARE AROUND THE WORLD.

MEDTRONIC ANNOUNCES MINIMED AS NAME FOR PLANNED NEW DIABETES COMPANY

GALWAY, IRELAND , MAY 23, 2025 /PRNEWSWIRE/ --MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED IT WILL PARTICIPATE IN BERNSTEIN'S 41ST STRATEGIC DECISIONS CONFERENCE ON THURSDAY, MAY 29, 2025. GEOFF MARTHA, MEDTRONIC CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL MAKE A FORMAL PRESENTATION BEGINNING AT 11:00 A.M.

MEDTRONIC CHAIRMAN AND CEO GEOFF MARTHA TO SPEAK AT BERNSTEIN'S STRATEGIC DECISIONS CONFERENCE

BUILDING MOMENTUM IN KEY FRANCHISES INCLUDING PULSED FIELD ABLATION, TAVR, CARDIAC RHYTHM MANAGEMENT, DIABETES, SPINE, AND NEUROMODULATION GALWAY, IRELAND , MAY 21, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FOURTH QUARTER (Q4) AND FISCAL YEAR 2025 (FY25), WHICH ENDED APRIL 25, 2025. Q4 KEY HIGHLIGHTS Q4 REVENUE OF $8.9 BILLION INCREASED 3.9% AS REPORTED AND 5.4% ORGANIC Q4 GAAP DILUTED EPS OF $0.82 INCREASED 67%; NON-GAAP DILUTED EPS OF $1.62 INCREASED 11% Q4 OPERATING MARGIN INCREASED 380 BASIS POINTS; Q4 NON-GAAP OPERATING MARGIN INCREASED 90 BASIS POINTS Q4 OPERATING PROFIT OF $1.4 BILLION INCREASED 36%; Q4 NON-GAAP OPERATING PROFIT OF $2.5 BILLION INCREASED 8% CARDIAC ABLATION SOLUTIONS Q4 REVENUE INCREASED NEARLY 30% ON STRENGTH OF PULSED FIELD ABLATION (PFA) PRODUCTS; BUSINESS DELIVERED $1.0 BILLION IN FY25 REVENUE SUBMITTED HUGO RAS SYSTEM TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR A UROLOGIC INDICATION IN THE FIRST QUARTER OF CALENDAR 2025 COMMENCED LARGEST BRAIN-COMPUTER INTERFACE LAUNCH FOLLOWING U.S. FDA APPROVAL OF BRAINSENSE ADAPTIVE DEEP BRAIN STIMULATION (ADBS) ADDITIONAL KEY HIGHLIGHTS FY25 REVENUE OF $33.5 BILLION, ADJUSTED REVENUE OF $33.6 BILLION, INCREASED 3.6% AS REPORTED AND 4.9% ORGANIC FY25 GAAP DILUTED EPS OF $3.61 INCREASED 31%; NON-GAAP DILUTED EPS OF $5.49 INCREASED 6% FY25 OPERATING MARGIN INCREASED 190 BASIS POINTS; FY25 NON-GAAP OPERATING MARGIN INCREASED 10 BASIS POINTS, 100 BASIS POINTS CONSTANT CURRENCY FY25 OPERATING PROFIT OF $6.0 BILLION INCREASED 16%; FY25 NON-GAAP OPERATING PROFIT OF $8.7 BILLION INCREASED 5%, 9% CONSTANT CURRENCY FY25 CASH FROM OPERATIONS OF $7.0 BILLION; FY25 FREE CASH FLOW OF $5.2 BILLION COMPANY RETURNED $6.3 BILLION TO SHAREHOLDERS IN FY25 DIVIDEND FOR Q1 FY26 INCREASED TO $0.71 PER SHARE, IMPLYING ANNUAL $2.84 PER SHARE; 48TH CONSECUTIVE YEAR OF DIVIDEND INCREASES ANNOUNCED TODAY INTENT TO SEPARATE DIABETES B

MEDTRONIC REPORTS STRONG FINISH TO ITS FISCAL YEAR WITH ITS FOURTH QUARTER FINANCIAL RESULTS; ANNOUNCES DIVIDEND INCREASE

ENABLES INTENSE FOCUS ON HIGHEST MARGIN GROWTH DRIVERS WHERE MEDTRONIC HAS LEADING CORE COMPETENCIES LEADING, SCALED, DIRECT-TO-CONSUMER DIABETES BUSINESS POISED TO BECOME STANDALONE COMPANY; ONLY COMPANY WITH A COMPLETE ECOSYSTEM TO ADDRESS INTENSIVE INSULIN MANAGEMENT GALWAY, IRELAND , MAY 21, 2025 /PRNEWSWIRE/ -- MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED ITS INTENT TO SEPARATE ITS DIABETES BUSINESS INTO A NEW STANDALONE COMPANY ("NEW DIABETES COMPANY"). THIS STRATEGIC DECISION FOR BOTH MEDTRONIC AND NEW DIABETES COMPANY WILL CREATE A MORE FOCUSED MEDTRONIC, WITH A MORE SIMPLIFIED PORTFOLIO IN HIGH MARGIN GROWTH MARKETS.

MEDTRONIC ANNOUNCES INTENT TO SEPARATE DIABETES BUSINESS

GALWAY, IRELAND , MAY 7, 2025 /PRNEWSWIRE/ --MEDTRONIC PLC (NYSE: MDT), A GLOBAL LEADER IN HEALTHCARE TECHNOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL FISCAL YEAR 2025 ON WEDNESDAY, MAY 21, 2025. A NEWS RELEASE WILL BE ISSUED AT APPROXIMATELY 5:45 A.M.

MEDTRONIC TO ANNOUNCE FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL FISCAL YEAR 2025

STAR JONES, AWARD WINNING TELEVISION PERSONALITY & WOMEN'S HEART HEALTH ADVOCATE, HELPS KICK OFF HEART HEALTH CONVERSATIONS THIS MOTHER'S DAY WITH THE MEDTRONIC 'LETTER TO MY MOTHER' CAMPAIGN GALWAY, IRELAND , MAY 7, 2025 /PRNEWSWIRE/ -- A NEW MEDTRONIC-SPONSORED SURVEY OF WOMEN AGES 30-50 REVEALS A SIGNIFICANT GAP IN AWARENESS AND DISCUSSION AROUND HEART HEALTH AMONG WOMEN AND THEIR MOTHER-FIGURES. DESPITE CARDIOVASCULAR DISEASE BEING THE #1 KILLER OF WOMEN IN THE U.S., MANY WOMEN ARE STILL UNAWARE OF THE RISK AND THE IMPORTANCE OF HEART HEALTH.

Medtronic plc

MDT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Medtronic plc

MDT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MDT